MID-VOLUME · FEMALE-LED
bimatoprost Side Effects
bimatoprost (also sold as Lumigan) sits MID-VOLUME #199 of 524 by FAERS report count. Lead signal: FEMALE-LED - 74% of sex-coded reports are female (19,549 F / 6,867 M). Demographics and serious-outcome tables follow.
Data updated 2026-05-15
- 28,128
- FAERS reports
FDA Adverse Event Reporting System extract for bimatoprost. Stamp set CASELOAD · DEATH-MARKED · HOSP-MID. How figures are compiled.
bimatoprost reporting skew - 74% of sex-coded reports are female (19,549 F / 6,867 M). Volume band MID-VOLUME #199 of 524 by FAERS report count; caseload CASELOAD.
Mid-book FAERS page for bimatoprost (Lumigan) (28,128 reports). Signature FEMALE-LED. Dominant age band on file: 75+. Educational reference only.
Counts from the openFDA FAERS extract (2004–2025). Stamps CASELOAD · DEATH-MARKED · HOSP-MID · FEMALE-LED.
TREATMENT FAILURE leads 3,077 of 28,128 reports
FEMALE-LED reporters · age peak 75+
Female-led reporters (74% of sex-coded rows)
Age peak 75+ (3,962 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death appears on 761 reports (2.7% - MARKED). Reactions below co-occur in those rows only.
| Reaction | Reports |
|---|---|
| DEATH | 377 |
| DIARRHOEA | 44 |
| PNEUMONIA | 44 |
| ASTHENIA | 40 |
| FALL | 36 |
| CARDIAC FAILURE CONGESTIVE | 34 |
| DYSPNOEA | 33 |
| FATIGUE | 32 |
| ANAEMIA | 30 |
| VOMITING | 30 |
| PAIN | 25 |
| PLEURAL EFFUSION | 25 |
| MYOCARDIAL INFARCTION | 24 |
| RENAL FAILURE | 23 |
| RESPIRATORY FAILURE | 23 |
| WEIGHT DECREASED | 23 |
| CEREBROVASCULAR ACCIDENT | 22 |
| HYPOTENSION | 22 |
| ATRIAL FIBRILLATION | 21 |
| CARDIAC FAILURE | 21 |
Reactions in Hospitalization Reports
Hospitalization mid-share (3,060, 10.9%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| FALL | 276 |
| DYSPNOEA | 247 |
| PNEUMONIA | 225 |
| ASTHENIA | 201 |
| FATIGUE | 199 |
| DIARRHOEA | 196 |
| NAUSEA | 149 |
| DIZZINESS | 138 |
| VOMITING | 137 |
| ANAEMIA | 135 |
| MALAISE | 113 |
| WEIGHT DECREASED | 113 |
| URINARY TRACT INFECTION | 112 |
| HEADACHE | 109 |
| PAIN | 109 |
| PYREXIA | 101 |
| PAIN IN EXTREMITY | 100 |
| ATRIAL FIBRILLATION | 99 |
| DEHYDRATION | 98 |
| CARDIAC FAILURE CONGESTIVE | 95 |
How to read bimatoprost FAERS figures (CASELOAD · DEATH-MARKED · HOSP-MID)
FAERS holds 28,128 voluntary reports linked to bimatoprost (Lumigan), 2004-2025. Death is listed on 761 (2.7%). Hospitalization appears on 3,060 (10.9%). Top co-reported indication: Product Used For Unknown Indication.
Mid-volume extract - treat DEATH-MARKED · HOSP-MID as signal-detection rates next to 74% of sex-coded reports are female (19,549 F / 6,867 M).
Read with bimatoprost
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-MID stamps.
ABS(total_reports) peer at 28,005 FAERS cases (Δ 123 lighter vs bimatoprost); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 27,931 FAERS cases (Δ 197 lighter vs bimatoprost); DEATH-MARKED · HOSP-MID · SEX-BALANCED vs this page's CASELOAD · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 28,434 FAERS cases (Δ 306 heavier vs bimatoprost); DEATH-HEAVY · HOSP-MID · FEMALE-LED vs this page's CASELOAD · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 28,498 FAERS cases (Δ 370 heavier vs bimatoprost); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 59.4 pp vs bimatoprost's DEATH-MARKED): CASELOAD · HOSP-MID.
bimatoprost sits in CASELOAD; high report volume tracks exposure and reporting culture more than per-patient risk. Methodology states the de-dup rules.